CN107454904A - 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域 - Google Patents

对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域 Download PDF

Info

Publication number
CN107454904A
CN107454904A CN201680019907.XA CN201680019907A CN107454904A CN 107454904 A CN107454904 A CN 107454904A CN 201680019907 A CN201680019907 A CN 201680019907A CN 107454904 A CN107454904 A CN 107454904A
Authority
CN
China
Prior art keywords
ala
ankyrin repeat
leu
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680019907.XA
Other languages
English (en)
Chinese (zh)
Inventor
T·巴克
M·T·斯通普
H·K·宾茨
D·菲利普斯
I·多拉多
P·福雷尔
F·W·默茨
I·松德雷格
D·斯泰纳
M·古罗迪-格奥尔吉耶娃
J·阿布拉姆萨力巴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of CN107454904A publication Critical patent/CN107454904A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
CN201680019907.XA 2015-04-02 2016-04-01 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域 Pending CN107454904A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15162511.8 2015-04-02
EP15162502.7 2015-04-02
EP15162511 2015-04-02
EP15162502 2015-04-02
PCT/EP2016/057272 WO2016156596A1 (en) 2015-04-02 2016-04-01 Designed ankyrin repeat domains with binding specificity for serum albumin

Publications (1)

Publication Number Publication Date
CN107454904A true CN107454904A (zh) 2017-12-08

Family

ID=55650423

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680019907.XA Pending CN107454904A (zh) 2015-04-02 2016-04-01 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域

Country Status (20)

Country Link
US (3) US9458211B1 (https=)
EP (2) EP3277711B9 (https=)
JP (1) JP6552636B2 (https=)
KR (2) KR102427117B1 (https=)
CN (1) CN107454904A (https=)
AU (3) AU2016240220B2 (https=)
BR (1) BR112017020986A2 (https=)
CA (1) CA2979602C (https=)
CL (1) CL2017002454A1 (https=)
CO (1) CO2017009954A2 (https=)
ES (1) ES2953482T3 (https=)
IL (2) IL276944B (https=)
MX (2) MX393655B (https=)
MY (1) MY179505A (https=)
NZ (1) NZ735803A (https=)
PH (1) PH12017501792B1 (https=)
RU (1) RU2769470C2 (https=)
SA (1) SA517390092B1 (https=)
SG (1) SG11201707606RA (https=)
WO (1) WO2016156596A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206943A (zh) * 2019-06-04 2022-03-18 分子伴侣公司 多特异性蛋白质
CN114206908A (zh) * 2019-06-04 2022-03-18 分子伴侣公司 具有改善的稳定性的经设计的锚蛋白重复结构域
CN114269366A (zh) * 2019-06-04 2022-04-01 分子伴侣公司 重组fap结合蛋白及其用途
CN114957426A (zh) * 2022-06-02 2022-08-30 华南师范大学 Sp6rars及其在防治蜚蠊目昆虫中的应用
CN115916815A (zh) * 2020-05-06 2023-04-04 分子合作伙伴股份公司 新型锚蛋白重复结合蛋白及其用途

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
PL2643349T3 (pl) * 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
CN117343192A (zh) * 2017-07-12 2024-01-05 四川科伦博泰生物医药股份有限公司 双特异性重组蛋白
KR20200038303A (ko) * 2017-08-18 2020-04-10 캠브리지 엔터프라이즈 리미티드 모듈형 결합 단백질
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
KR20220044612A (ko) * 2019-03-22 2022-04-08 리플렉시온 파마슈티컬스, 인크. Vegf에 대한 d-펩티드성 화합물
CN114222757A (zh) 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
US20240279290A1 (en) * 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
US20240279309A1 (en) * 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
AU2021403658A1 (en) 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use
AU2021403833A1 (en) * 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
BR112023018293A2 (pt) * 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
CA3211368A1 (en) * 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
US20240317852A1 (en) 2021-03-09 2024-09-26 Molecular Partners Ag Novel darpin based cd33 engagers
WO2022215032A1 (en) * 2021-04-09 2022-10-13 Molecular Partners Ag Novel darpin based cd70 engagers
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
EP4724486A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
WO2024251695A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd47 binding proteins and their use
EP4724460A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd16a binding proteins and their use
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025146487A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Multispecific binding proteins
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025146490A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use
WO2025163083A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recobminant dll3 binding proteins and their use
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager
WO2026013280A1 (en) 2024-07-11 2026-01-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Designed ankyrin repeat proteins binding p53, and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
CN103459422A (zh) * 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
CN103459415A (zh) * 2010-11-26 2013-12-18 分子组合公司 设计的与血清白蛋白结合的重复蛋白
WO2014191574A1 (en) * 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2805618A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
CN103459422A (zh) * 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
CN103459415A (zh) * 2010-11-26 2013-12-18 分子组合公司 设计的与血清白蛋白结合的重复蛋白
WO2014191574A1 (en) * 2013-05-31 2014-12-04 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206943A (zh) * 2019-06-04 2022-03-18 分子伴侣公司 多特异性蛋白质
CN114206908A (zh) * 2019-06-04 2022-03-18 分子伴侣公司 具有改善的稳定性的经设计的锚蛋白重复结构域
CN114269366A (zh) * 2019-06-04 2022-04-01 分子伴侣公司 重组fap结合蛋白及其用途
CN114206908B (zh) * 2019-06-04 2025-12-23 分子伴侣公司 具有改善的稳定性的经设计的锚蛋白重复结构域
CN115916815A (zh) * 2020-05-06 2023-04-04 分子合作伙伴股份公司 新型锚蛋白重复结合蛋白及其用途
CN114957426A (zh) * 2022-06-02 2022-08-30 华南师范大学 Sp6rars及其在防治蜚蠊目昆虫中的应用
CN114957426B (zh) * 2022-06-02 2023-05-16 华南师范大学 Sp6rars及其在防治蜚蠊目昆虫中的应用

Also Published As

Publication number Publication date
CO2017009954A2 (es) 2018-02-20
SA517390092B1 (ar) 2022-03-03
RU2769470C2 (ru) 2022-04-01
JP6552636B2 (ja) 2019-07-31
US20160289285A1 (en) 2016-10-06
RU2017134456A (ru) 2019-04-03
EP4272838A2 (en) 2023-11-08
MX2022008302A (es) 2023-02-28
US20160362453A1 (en) 2016-12-15
JP2018511327A (ja) 2018-04-26
EP4272838A3 (en) 2024-01-10
AU2016240220B2 (en) 2019-11-21
SG11201707606RA (en) 2017-10-30
KR20170131515A (ko) 2017-11-29
ES2953482T3 (es) 2023-11-13
US9458211B1 (en) 2016-10-04
EP3277711B9 (en) 2023-08-16
EP3277711A1 (en) 2018-02-07
BR112017020986A2 (pt) 2018-08-14
US11332501B2 (en) 2022-05-17
KR102427117B1 (ko) 2022-07-29
US10155791B2 (en) 2018-12-18
WO2016156596A1 (en) 2016-10-06
IL254788B (en) 2020-09-30
AU2021286418A1 (en) 2022-01-20
AU2016240220A1 (en) 2017-10-19
CA2979602A1 (en) 2016-10-06
MX393655B (es) 2025-03-24
IL276944B (en) 2022-07-01
IL276944A (en) 2020-10-29
IL254788A0 (en) 2017-12-31
PH12017501792A1 (en) 2019-01-21
RU2017134456A3 (https=) 2019-10-08
EP3277711B1 (en) 2023-06-07
AU2021286418B2 (en) 2024-01-04
HK1244009A1 (en) 2018-07-27
AU2020201264A1 (en) 2020-03-12
PH12017501792B1 (en) 2022-07-20
MY179505A (en) 2020-11-09
MX2017012485A (es) 2018-04-11
EP3277711C0 (en) 2023-06-07
CL2017002454A1 (es) 2018-05-25
CA2979602C (en) 2022-12-20
NZ735803A (en) 2021-12-24
KR20220109488A (ko) 2022-08-04
US20190263869A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
AU2021286418B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
JP6976335B2 (ja) 組み換え結合タンパク質及びその使用
CN115925977B (zh) 双特异性融合多肽及其应用
HK1244009B (en) Designed ankyrin repeat domains with binding specificity for serum albumin
CN117242100A (zh) 基于DARPin的新型CD70接合物
HK1213001B (zh) 与肝细胞生长因子结合的设计锚蛋白重复蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination